Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- PharmaEngine
- Target Recruit Count
- 12
- Registration Number
- NCT02901483
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital (Lovers Lake Branch), Keelung, Taiwan
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 41
- Registration Number
- NCT02901301
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- Conditions
- Mesothelioma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 605
- Registration Number
- NCT02899299
- Locations
- 🇺🇸
Local Institution - 0014, New Haven, Connecticut, United States
🇺🇸Local Institution - 0013, Detroit, Michigan, United States
🇺🇸Local Institution - 0004, Rochester, Minnesota, United States
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT02899728
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
- Conditions
- Solid NeoplasmStage IIIA Non-Small Cell Lung CancerStage IVA Pancreatic CancerSarcomaCancer of Unknown PrimaryStage III Pancreatic CancerStage IIIA Breast CancerColorectal CancerStage IIIB Breast CancerStage IV Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Emory University
- Target Recruit Count
- 71
- Registration Number
- NCT02897375
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaPeritoneal Carcinomatosis
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02891447
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung Cancer
- Interventions
- Drug: DocetaxelDrug: Gemcitabine/CisplatinDrug: Docetaxel/OxaliplatinDrug: Docetaxel/CarboplatinDrug: Gemcitabine/CarboplatinDrug: PlaceboDrug: CarboplatinDrug: Cisplatin
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 500
- Registration Number
- NCT02889666
- Locations
- 🇨🇳
China-Japan Union Hospital, Jilin University, Changchun, Jilin, China
🇨🇳Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
🇨🇳Shanghai 10th People's Hospital, Shanghai, China
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT02885974
- Locations
- 🇺🇸
Baylor Clinic, Houston, Texas, United States
🇺🇸Harris Health System - Smith Clinic, Houston, Texas, United States
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02886195
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT02882308
- Locations
- 🇬🇷
Euromedica General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece
🇬🇷University Hospital "Attikon", 2nd Department of Internal Medicine, Division of Oncology, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.